Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT07412470 |
| Consolidated Lead Sponsor | Sanofi |
| Therapeutic Condition Cohort | Immunology, Rheumatology, and Dermatology |
| Clinical Trial Phase | Phase II/III |
| Overall Recruitment Status | RECRUITING |
| Registered Enrollment | 526 participants (ESTIMATED) |
| Registered Start Date | 2026-03-13 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| UCSF Medical Center and Helen Diller Cancer Center | San Francisco, CA | Open Hospital Dossier -> |
| Emory Winship Cancer Institute | Atlanta, GA | Open Hospital Dossier -> |
| Brigham and Women's Hospital | Boston, MA | Open Hospital Dossier -> |
| University of Michigan Rogel Cancer Center | Ann Arbor, MI | Open Hospital Dossier -> |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Sanofi across sibling Meru public-data platforms.
Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.